Literature DB >> 18582601

Nonlinear model-based estimates of IC(50) for studies involving continuous therapeutic dose-response data.

Robert H Lyles1, Cliff Poindexter, Angelo Evans, Milton Brown, Carlton R Cooper.   

Abstract

We present statistical details for estimating an in vitro 50% inhibitory concentration (IC(50)), based on several models for continuous response data fit to bone-marrow endothelial cell lines replicated in vehicle and at several dose increments. Nonlinear models are fit via maximum likelihood assuming normal errors, and primary attention is given to exponential, Gompertz, and scaled logistic dose-response curves that admit increasing or decreasing monotonic and sigmoidal patterns. Careful consideration is given to dose axis scaling, comparative model fit via mean squared error and graphical assessment, analogues to weighted least squares analysis to address heterogeneity of variance across doses, and potential hormetic effects. Standard error estimation is discussed in detail, highlighting the advantage of reparameterizing dose-response models directly in terms of IC(50). Specific results for two cell lines are provided, along with a sample commercial software-based program for implementing a selection of the methods discussed.

Mesh:

Year:  2008        PMID: 18582601      PMCID: PMC2586183          DOI: 10.1016/j.cct.2008.05.009

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  7 in total

1.  Calculation of the EC50 and its confidence interval when subtoxic stimulus is present.

Authors:  P H Van Ewijk; J A Hoekstra
Journal:  Ecotoxicol Environ Saf       Date:  1993-02       Impact factor: 6.291

2.  Characterization of a newly established human bone marrow endothelial cell line: distinct adhesive properties for hematopoietic progenitors compared with human umbilical vein endothelial cells.

Authors:  K M Schweitzer; P Vicart; C Delouis; D Paulin; A M Dräger; M M Langenhuijsen; B B Weksler
Journal:  Lab Invest       Date:  1997-01       Impact factor: 5.662

3.  Analysis and comparison of sigmoidal curves: application to dose-response data.

Authors:  J B Meddings; R B Scott; G H Fick
Journal:  Am J Physiol       Date:  1989-12

4.  Angiogenesis in the bone marrow of patients with breast cancer.

Authors:  Mariana Chavez-Macgregor; Alejandro Aviles-Salas; Dan Green; Adolfo Fuentes-Alburo; Celedonio Gómez-Ruiz; Alvaro Aguayo
Journal:  Clin Cancer Res       Date:  2005-08-01       Impact factor: 12.531

5.  Isolation, characterization, and biologic features of bone marrow endothelial cells.

Authors:  G Almeida-Porada; J L Ascensão
Journal:  J Lab Clin Med       Date:  1996-10

6.  Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases.

Authors:  Colm Morrissey; Lawrence D True; Martine P Roudier; Ilsa M Coleman; Sarah Hawley; Peter S Nelson; Roger Coleman; Ya-Chun Wang; Eva Corey; Paul H Lange; Celestia S Higano; Robert L Vessella
Journal:  Clin Exp Metastasis       Date:  2007-10-31       Impact factor: 5.150

7.  Flavonoid inhibitors of trypsin and leucine aminopeptidase: a proposed mathematical model for IC50 estimation.

Authors:  J Parellada; M Guinea
Journal:  J Nat Prod       Date:  1995-06       Impact factor: 4.050

  7 in total
  12 in total

1.  Computer-aided identification of lead compounds as Staphylococcal epidermidis FtsZ inhibitors using molecular docking, virtual screening, DFT analysis, and molecular dynamic simulation.

Authors:  Swayansiddha Tripathy; Susanta Kumar Sahu; Mohammed Afzal Azam; Srikanth Jupudi
Journal:  J Mol Model       Date:  2019-11-26       Impact factor: 1.810

2.  Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions.

Authors:  Harma Ellens; Shibing Deng; Joann Coleman; Joe Bentz; Mitchell E Taub; Isabelle Ragueneau-Majlessi; Sophie P Chung; Krisztina Herédi-Szabó; Sibylle Neuhoff; Johan Palm; Praveen Balimane; Lei Zhang; Masoud Jamei; Imad Hanna; Michael O'Connor; Dallas Bednarczyk; Malin Forsgard; Xiaoyan Chu; Christoph Funk; Ailan Guo; Kathleen M Hillgren; Libin Li; Anne Y Pak; Elke S Perloff; Ganesh Rajaraman; Laurent Salphati; Jan-Shiang Taur; Dietmar Weitz; Heleen M Wortelboer; Cindy Q Xia; Guangqing Xiao; Tetsuo Yamagata; Caroline A Lee
Journal:  Drug Metab Dispos       Date:  2013-04-25       Impact factor: 3.922

3.  Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts.

Authors:  Jerec W Ricci; Debbie M Lovato; Virginia Severns; Larry A Sklar; Richard S Larson
Journal:  Mol Cancer Ther       Date:  2016-09-26       Impact factor: 6.261

4.  Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer.

Authors:  Na Zhao; Jin Cao; Longyong Xu; Qianzi Tang; Lacey E Dobrolecki; Xiangdong Lv; Manisha Talukdar; Yang Lu; Xiaoran Wang; Dorothy Z Hu; Qing Shi; Yu Xiang; Yunfei Wang; Xia Liu; Wen Bu; Yi Jiang; Mingzhou Li; Yingyun Gong; Zheng Sun; Haoqiang Ying; Bo Yuan; Xia Lin; Xin-Hua Feng; Sean M Hartig; Feng Li; Haifa Shen; Yiwen Chen; Leng Han; Qingping Zeng; John B Patterson; Benny Abraham Kaipparettu; Nagireddy Putluri; Frank Sicheri; Jeffrey M Rosen; Michael T Lewis; Xi Chen
Journal:  J Clin Invest       Date:  2018-02-26       Impact factor: 14.808

5.  A novel application of t-statistics to objectively assess the quality of IC50 fits for P-glycoprotein and other transporters.

Authors:  Michael O'Connor; Caroline Lee; Harma Ellens; Joe Bentz
Journal:  Pharmacol Res Perspect       Date:  2014-12-02

6.  Insights from molecular modeling, docking and simulation of imidazole nucleus containing chalcones with EGFR kinase domain for improved binding function.

Authors:  Gondu Eswara Rao; Sk Abdul Rahaman; A Prameela Rani
Journal:  Bioinformation       Date:  2016-04-10

7.  Metformin enhances the radiosensitizing effect of cisplatin in non-small cell lung cancer cell lines with different cisplatin sensitivities.

Authors:  Muhammad Assad Riaz; Ali Sak; Yasin Bahadir Erol; Michael Groneberg; Jürgen Thomale; Martin Stuschke
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

8.  In vitro selective cytotoxicity of the dietary chalcone cardamonin (CD) on melanoma compared to healthy cells is mediated by apoptosis.

Authors:  Lena Berning; Lisa Scharf; Elif Aplak; David Stucki; Claudia von Montfort; Andreas S Reichert; Wilhelm Stahl; Peter Brenneisen
Journal:  PLoS One       Date:  2019-09-25       Impact factor: 3.240

9.  The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells.

Authors:  Machiko Kojima; Kenbun Sone; Katsutoshi Oda; Ryuji Hamamoto; Syuzo Kaneko; Shinya Oki; Asako Kukita; Akira Kawata; Harunori Honjoh; Yoshiko Kawata; Tomoko Kashiyama; Masakazu Sato; Ayumi Taguchi; Yuichiro Miyamoto; Michihiro Tanikawa; Tetsushi Tsuruga; Kazunori Nagasaka; Osamu Wada-Hiraike; Yutaka Osuga; Tomoyuki Fujii
Journal:  Oncol Lett       Date:  2020-08-24       Impact factor: 2.967

10.  CNP mediated selective toxicity on melanoma cells is accompanied by mitochondrial dysfunction.

Authors:  Elif Aplak; Claudia von Montfort; Lisa Haasler; David Stucki; Bodo Steckel; Andreas S Reichert; Wilhelm Stahl; Peter Brenneisen
Journal:  PLoS One       Date:  2020-01-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.